Olanzapine And Samidorphan L-Malate has 8 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Dopamine Agonists, Levodopa. Patients taking Olanzapine And Samidorphan L-Malate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Major
- 3
- Moderate
- 5
Major (3)
- Olanzapine And Samidorphan L-Malate + Cyp3a Inducers— Coadministration decreases AUC and Cmax of olanzapine and samidorphan, which may reduce LYBALVI efficacy. Concomitant us…
- Olanzapine And Samidorphan L-Malate + Dopamine Agonists— Concomitant use is not recommended due to dopamine antagonism by olanzapine potentially reducing agonist efficacy.
- Olanzapine And Samidorphan L-Malate + Levodopa— Concomitant use is not recommended due to dopamine antagonism by olanzapine potentially reducing levodopa efficacy.
Moderate (5)
- Olanzapine And Samidorphan L-Malate + Acidifying Agents— LYBALVI may enhance the effects of certain antihypertensive agents. Monitor blood pressure and reduce dosage of antihype…
- Olanzapine And Samidorphan L-Malate + Alcohol— Concomitant use may potentiate orthostatic hypotension observed with olanzapine. LYBALVI should be used with caution.
- Olanzapine And Samidorphan L-Malate + Diazepam— Diazepam, Alcohol, and Other CNS Acting Drugs Clinical Implication: Concomitant use of diazepam, alcohol, or other CNS a…
- Olanzapine And Samidorphan L-Malate + Mao Inhibitors— Concomitant use increases olanzapine AUC and Cmax, which may increase the risk of LYBALVI adverse reactions. Consider re…
- Olanzapine And Samidorphan L-Malate + Short-Acting Antacids— Concomitant use may potentiate orthostatic hypotension observed with olanzapine. LYBALVI should be used with caution.